Drug-induced hepatitis with severe cholestasis due to voglibose

International Hepatology Communications

Volumn 5, Issue 4-5, 1996, Pages 289-296

  Masumoto, Toshikazu ^a   Ishikawa, Maki ^a   Yamauchi, Yuusuke ^a   Hiasa, Yoichi ^a   Yamamoto, Kazuhiro ^a   Iuchi, Hideto ^a   Ohkubo, Keiji ^a   Akbar, S M Fazle ^a   Michitaka, Kojiro ^a   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha D glucosidase inhibitor; Jaundice; Methicillin resistant Staphylococcus aureus; Noninsulin dependent diabetes mellitus

Indexed keywords

URSODEOXYCHOLIC ACID; VANCOMYCIN; VOGLIBOSE;

AGED; ARTICLE; CASE REPORT; CHOLESTASIS; HEPATITIS; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0030249644     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-4346(96)00310-6     Document Type: Article

References (12)

1. [1] Zimmerman HJ. Classification of hepatotoxins and mechanisms of toxicity. In: Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century Crofts. 1978; 91-121.
2. [2] Ikeda H, Horii S, Mastuo T. Smoothing action of a new potent alpha-glucosidase inhibitor, AO-128, on the postprandial hyperglycemia in rats and dogs. Twelfth Congress of the International Diabetes Federation 1985; S256: Suppl 661.
3. [3] Spengler M. Acarbose safety review. Pract Diabetes 1993; 10 (6): S28-S31.
4. [4] Caniff RF, Shapiro JA, Robins D, Kleinfield R, Seaton TB, Beisswenger P et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995; 18 (6): 817-824.
5. [5] Farrell GC. Drug-induced cholestasis. In: Farrell GC, ed. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994; 319-369.
6. [6] Mizoguchi T, Ohnishi F, Monna T, Yamamoto S, Nakai K, Otani S et al. Study on intrahepatic cholestasis: Intrahepatic cholesta sis induced in rats by the culture supernatant of activated lymphocytes. Hepato-gastroenterol 1981; 28: 292-295.
7. [7] Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet 1986; ii: 440-444.
8. [8] Pohl LR, Satoh H, Christ DD. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 1988; 28: 367-387.
9. [9] Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581-590.
10. [10] Hiraga K. Parmacokinetics of AO-128 and its influences on carbohydrate metabolism: a study in healthy volunteers [in Japanese]. Kiso to Rinshyo 1992; 26(1): 283-293.
11. [11] Sameshima Y, Shiozaki Y, Mizuno T, SasaKawa M. Drug-induced hepatitis: a review of the Japanese literature over the past 70 years [in Japanese]. Jpn J Gastoroenterol 1984; 81 (1): 37-45.
12. [12] Ichikawa S, Kitami N. A study of clinical features in patients with drug-induced allergic hepatic injury [in Japanese]. Acta Hepatol Jpn 1988; 30 (5): 553-558.